BCR and B-cell chronic lymphocytic leukemia: Consistently, the concomitant inhibition of BTK and PI3K by ibrutinib and idelalisib, respectively, has been shown to hamper BCR-stimulated integrin-mediated CLL cell adhesion in a strong synergistic manner (de Rooij et al., 2015).